Get the Stockscreener App
0.791
3.31%
-0.0271
After Hours:
.78
-0.011
-1.39%
Hoth Therapeutics Inc stock is traded at $0.791, with a volume of 84,656.
It is down -3.31% in the last 24 hours and down -14.81% over the past month.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
See More
Previous Close:
$0.8181
Open:
$0.8205
24h Volume:
84,656
Relative Volume:
0.02
Market Cap:
$5.52M
Revenue:
-
Net Income/Loss:
$-9.62M
P/E Ratio:
-0.1272
EPS:
-6.22
Net Cash Flow:
$-7.93M
1W Performance:
-11.12%
1M Performance:
-14.81%
6M Performance:
-32.97%
1Y Performance:
-26.89%
1-Day Range:
$0.79
$0.8401
1-Week Range:
$0.7601
$0.9038
52-Week Range:
$0.58
$1.73
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
590 MADISON AVENUE, NEW YORK, NY
Compare HOTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| HOTH | 0.791 | 5.52M | 0 | -9.62M | -7.93M | -6.22 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Hoth Therapeutics shares hold buy as study shows cancer treatment promise - Investing.com
Hoth Therapeutics Receives Notification from Nasdaq Due to Minimum Bid Price Non-Compliance - Defense World
Hoth Therapeutics faces Nasdaq delisting over stock price By Investing.com - Investing.com Australia
Hoth Therapeutics faces Nasdaq delisting over stock price - Investing.com
Hoth Therapeutics reports stable tumor growth in study By Investing.com - Investing.com Canada
Hoth Therapeutics Up 34% on Favorable Early Data for Preclinical Study of Cancer Drug - MarketWatch
Hoth Therapeutics reports stable tumor growth in study - Investing.com
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study - PR Newswire
Top investors say Hoth Therapeutics Inc (HOTH) ticks everything they need - SETE News
Hoth Therapeutics Inc [HOTH] Is Currently 8.11 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
Hoth Therapeutics secures patent, analyst maintains steady target - Investing.com
Hoth Therapeutics secures patent, analyst maintains steady target By Investing.com - Investing.com UK
Hoth Therapeutics secures US patent for Alzheimer's drug By Investing.com - Investing.com Australia
HOTH’s Stock Market Adventure: -43.06% YTD Growth Amidst Volatility - The InvestChronicle
Hoth Therapeutics secures US patent for Alzheimer's drug - Investing.com India
Financial Metrics Check: Hoth Therapeutics Inc (HOTH)’s Ratios for Trailing Twelve Months - The Dwinnex
Hoth Shares Rise After Alzheimer's Treatment Gets Patent - MarketWatch
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway - PR Newswire
Benchmark keeps Speculative Buy rating on Hoth shares on robust pipeline By Investing.com - Investing.com Canada
Benchmark keeps Speculative Buy rating on Hoth shares on robust pipeline - Investing.com
Hoth Therapeutics, Wise Systems Partner To Leverage AI For Drug Discovery - Contract Pharma
Micro Cap Already Off To The Races At The Bell - MSN
Hoth Therapeutics, Inc. (NASDAQ:HOTH) Sees Significant Increase in Short Interest - Defense World
EGFR Inhibitors-Induced Skin Disorders Market Growth - openPR
Buy Honasa Consumer, target price Rs 530: JM Financial - The Economic Times
Examining the Potential Price Growth of Holley Inc (HLLY) - Knox Daily
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Harrow Inc (HROW) Becoming More Attractive for Investors - Knox Daily
Davidson Kempner Capital Management LP Invests $3.21 Million in Loar Holdings, LLC (NYSE:LOAR) - Defense World
Why Investors Shouldn't Be Surprised By THOR Industries, Inc.'s (NYSE:THO) P/E - Simply Wall St
Lombard Odier Asset Management USA Corp Invests $786,000 in Hilton Grand Vacations Inc. (NYSE:HGV) - Defense World
THG Plunges 24% ATO amid Internal Frauds by Subsidiaries - KAOHOON INTERNATIONAL
Holley Inc. (NYSE:HLLY) Shares Sold by Kayne Anderson Rudnick Investment Management LLC - Defense World
Capstone Triton Financial Group LLC Has $707,000 Stock Position in Honeywell International Inc. (NASDAQ:HON) - Defense World
Hoth Therapeutics (NASDAQ:HOTH) Trading Down 3% - Defense World
Highbridge Capital Management LLC Purchases Shares of 630,114 HashiCorp, Inc. (NASDAQ:HCP) - MarketBeat
Haoxi Health Technology Down 75% After $12M Offering - MarketWatch
The time has not yet come to remove your chips from the table: Hoth Therapeutics Inc (HOTH) - SETE News
Hoth Therapeutics Inc (HOTH) gets rating Initiated from The Benchmark Company - Knox Daily
Hoth Therapeutics Inc [HOTH] Revenue clocked in at $0.00 million, down -25.69% YTD: What’s Next? - The DBT News
Balance Sheet Dive: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Choreo LLC Purchases New Shares in The Hanover Insurance Group, Inc. (NYSE:THG) - Defense World
C4 Therapeutics Inc (NASDAQ: CCCC) Up 14.34% This Year: What To Expect Next - Stocks Register
Hoth Therapeutics Inc (HOTH) Stock: Navigating a Year of Volatility - The InvestChronicle
Hoth Therapeutics Shares Rally on Positive Alzheimer's Pre-clinical Study Data - MarketWatch
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ - PR Newswire
Monopar Therapeutics' (MNPR) MNPR-101-Zr Shows Promising Tumor Targeting in Early Clinical Trial - BP Journal
Hoth Therapeutics Inc (HOTH) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Market Watch Highlights: Hoth Therapeutics Inc (HOTH) Ends on an Upturn Note at 1.12 - The Dwinnex
Hoth Therapeutics Inc [HOTH] Stock bought by Insider Knie Robb for $16750.0 - Knox Daily
AstraZeneca (NASDAQ: AZN) Stock Dips on Lung Cancer Drug Trial Setback - ABBO News
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):